|1.||Feldman, Steven R: 15 articles (01/2015 - 05/2002)|
|2.||Colón, Luz E: 7 articles (10/2011 - 11/2007)|
|3.||Koo, John Y M: 6 articles (02/2015 - 06/2002)|
|4.||Menter, Alan: 6 articles (02/2012 - 05/2002)|
|5.||Johnson, Lori A: 6 articles (10/2011 - 01/2008)|
|6.||Koo, John: 5 articles (09/2013 - 05/2002)|
|7.||Lebwohl, Mark: 5 articles (06/2008 - 05/2002)|
|8.||Gottschalk, Ronald W: 4 articles (11/2012 - 01/2009)|
|9.||Hudson, Charles P: 4 articles (10/2011 - 02/2011)|
|10.||Papp, Kim: 4 articles (10/2011 - 01/2010)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/1987 - "Although it would appear that there was no clear preference for continuous therapy, other studies involving larger numbers of patients are needed to determine whether intermittent therapy with a potent corticosteroid such as clobetasol propionate is equally as effective in psoriasis."
06/01/2006 - "Clobetasol propionate is a very effective treatment for psoriasis. "
04/01/2006 - "Clobetasol propionate is known to be a very effective treatment for psoriasis; however, its use is limited by potent corticosteroid class related side effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression and atrophogenicity. "
11/01/2012 - "When clobetasol propionate 0.05% spray was used as monotherapy or as an add-on therapy for 4 weeks in a large, observational trial, approximately 80% of patients experienced consistent and significant improvement in QOL on 2 separate, validated QOL instruments (DLQI and the Koo-Menter Psoriasis Index). "
11/01/2012 - "In another randomized trial in patients with moderate to severe plaque psoriasis, clobetasol propionate 0.05% spray produced significantly greater reductions in mean affected body surface area and significantly greater improvements in QOL, as measured by the Dermatology Life Quality Index (DLQI), compared with a 0.05% foam formulation. "
|2.||Lichen Sclerosus et Atrophicus (Lichen Sclerosus)
09/01/1998 - "Clobetasol propionate cream is recommended for treatment of lichen sclerosus, with a 77% chance of complete remission of symptoms and a 47% chance of improvement in the clinical appearance of the vulva. "
03/01/1999 - "Treatment with clobetasol propionate 0.05% cream is effective against lichen sclerosus et atrophicus (LSA) of the vulva. "
09/01/1998 - "To assess the efficacy of treating lichen sclerosus with clobetasol propionate. "
07/01/2014 - "At the end of the study, 28 participants (19 tacrolimus and 9 clobetasol) still had some clinical signs of lichen sclerosus (χ(2) = 6.56, P = .015). "
03/01/1999 - "Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study."
|3.||Vulvar Lichen Sclerosus
10/01/2001 - "Clobetasol propionate was an effective treatment of premenarchal vulvar lichen sclerosus in this small group; however, recurrences were common and required additional steroid treatment. "
06/01/2004 - "To analyze the rates of remission, recurrence, and chronic evolution of vulvar lichen sclerosus (VLS) treated with 0.05% clobetasol propionate ointment and determine whether this treatment can decrease the risk of malignant evolution. "
01/01/2011 - "This study investigates the health-related quality of life in patients with vulvar lichen sclerosus (LS) and the patient-defined therapeutic benefit of clobetasol. "
01/01/2002 - "Clobetasol propionate 0.05% has been the mainstay in treating vulvar lichen sclerosus (VLS) for the past ten years. "
01/01/2002 - "Vulvar lichen sclerosus in postmenopausal women: a comparative study for treating advanced disease with clobetasol propionate 0.05%."
06/01/2002 - "Erythema improved significantly more in clobetasol-treated lesions (P <.05) during the treatment period, but differences became statistically insignificant during the post-treatment period (;P =.20). "
05/01/2003 - "At Week 2 (or end of treatment), 68% (94/139) of patients who received clobetasol foam had a Physician's Static Global Assessment score of 0 (clear, except for minor residual discoloration) or 1 (majority of lesions have individual scores for plaque thickness, erythema, and scaling that averages 1). "
11/01/2006 - "Overall, clobetasol propionate spray 0.05% administered twice daily for 4 weeks was effective and safe in reducing scaling, erythema, plaque elevation, and overall disease severity and demonstrates durable clinical response up to 4 weeks after treatment end."
01/01/2006 - "Clobetasol propionate shampoo was superior to tar blend shampoo with respect to all efficacy variables tested (p<0.001): Total and Global Severity Score; erythema; plaque thickening; desquamation; pruritus; total scalp area involved; and the subject's global assessment of clinical improvement. "
09/01/2006 - "At weeks 4, 6, and 8, significantly greater proportions of patients treated with tacrolimus had improved erythema and desquamation compared with those treated with clobetasol (all, P < 0.001). "
|5.||Oral Lichen Planus
05/01/2011 - "A patient suffering from a mixed atrophic-erosive form of oral lichen planus (OLP), with serious gingival involvement, was also treated with the topical application of clobetasol propionate 0.05% using gingival trays. "
09/01/2010 - "HPA-suppressive effects of aqueous clobetasol propionate in the treatment of patients with oral lichen planus."
02/01/2009 - "Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations."
01/01/1992 - "[Occlusive treatment of atrophic and erosive oral lichen planus with Clobetasol Propionate 0.05% ointment (Dermovat)]."
06/01/2014 - "Efficacy of laser phototherapy in comparison to topical clobetasol for the treatment of oral lichen planus: a randomized controlled trial."
|2.||mometasone furoate (mometasone)
|3.||Adrenal Cortex Hormones (Corticosteroids)
|4.||Clobetasol (Clobetasol Propionate)
|1.||Hydrocolloid Bandages (Duoderm)
|4.||Drug Therapy (Chemotherapy)
|5.||Low-Level Laser Therapy (LLLT)